RxDoctor Payments Data

Nguyet le, MD

Family Medicine · Anaheim, CANPI 1154346542

Payments from drug & device makers

$1,424in general payments, 2019–2025

Across 51 payments — averaging $27.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$335
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$188
  • Lilly USA, LLC$150
  • AbbVie$132
  • Merck$106
  • Amgen$103
  • plus $410 from 10 others

What the payments were for

  • Food & beverage$1,424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,424 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$129,256
Medicare patients
161
Services billed
1,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FanaptIloperidone26$58,674
OzempicSemaglutide45$49,695
JardianceEmpagliflozin28$34,685
MounjaroTirzepatide31$32,885
ZyprexaOlanzapine13$30,417
RybelsusSemaglutide18$26,803
XareltoRivaroxaban57$24,474
LinzessLinaclotide41$24,107
Tresiba Flextouch U-200Insulin Degludec25$19,307
JanuviaSitagliptin Phosphate19$18,803
EliquisApixaban18$18,552
ProliaDenosumab11$17,864
FarxigaDapagliflozin Propanediol21$16,342
TrulicityDulaglutide11$13,442
EntrestoSacubitril/Valsartan16$12,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Zyprexa, Trulicity, Olanzapine$150$78,18596 claims
Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30$25$77,93080 claims
Vanda Pharmaceuticals Inc.Fanapt$30$58,67426 claims
AbbVieLinzess, Restasis$132$36,99557 claims
MerckJanuvia$106$18,80319 claims
AmgenProlia$103$17,86411 claims
AstraZenecaFarxiga$20$16,34221 claims
GSKBreo Ellipta$89$7,82321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →